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Cardio-Oncology for the 21st Century: Introduction

Based on the latest statistics the prognosis for patients with malignancy has
dramatically improved. The overall 5 year survival rate for those who were
diagnosed with a cancer between 2002 and 2008 was approximately 65%1, and as
of 2008, 12 million Americans were cancer survivors.2 However, this extended
longevity now exposes these patients to the risk of other health issues related to
their primary cancer or to the treatment that ensured their survival. Specifically,
patients who have not succumbed prematurely to their oncologic disease may
develop cardiovascular disease that is either a result of the long-term effects of their
traditional cardiovascular risk factors or that is due to the direct cardiovascular
toxicity of the cancer itself or from the administered therapy. In fact, Patnaik and
colleagues reviewed the Surveillance, Epidemiology, and End Results (SEER)Medicare linked database and found that breast cancer survivors were as likely to
die from cardiovascular disease as from recurrent breast cancer.3 Additionally,
Mertens and colleagues found that cardiovascular events are the leading cause of
nonmalignant deaths in survivors of childhood cancers.4

Because of the ongoing need for recurrent cancer monitoring, the treating
oncologist may be the de facto primary care physician for many oncologic patients.
Also, the treating oncologist is the most knowledgeable physician with regard to the
possible toxicities related to a patient’s cancer and any administered therapy.
Therefore, in addition to monitoring these patients for recurrent oncologic disease,
it is the treating oncologist’s responsibility to be cognizant of other long-term health
complications to which these patients are susceptible. This special edition of
Seminars in Oncology reviews the cardiovascular issues that can arise during the
ongoing care of oncologic patients.

Cardiovascular disease assessment begins with a careful history that includes
questions about the presence of symptoms that may not be part of the usual review
of systems associated with cancer patients. A change in exercise tolerance either
due to chest/neck/shoulder discomfort or dyspnea, complaints of near- syncope or
syncope, feelings of rapid or irregular palpitations, or an awareness of peripheral
edema or pulmonary congestion may be indicators of cardiac decompensation.
Additionally, in order to complete the cardiovascular history, the presence of known
risk factorshypertension, hyperlipidemia, diabetes, physical inactivity, significant
family history, and tobacco/alcohol usageshould be assessed.

During a cancer patient’s physical examination, the oncologist needs to include a
careful evaluation of the cardiovascular system, including the measurement of

accurate vital signs (blood pressure should be obtained with the arm held at heart
level while the patient is sitting on a chair, feet on the floor, after 5 minutes of
relaxation5), assessment of the jugular venous pressure, auscultation for the
presence of arterial bruits as well as for cardiac murmurs, gallops, and rubs, and
observation for signs of hypervolemia (e.g., pulmonary congestion, edema, ascites,
hepatic congestion).

Based on this history and physical examination, a cancer patient may require
further cardiac tests such as electrocardiograms, echocardiograms, nuclear imaging
scans, and biomarker measurements. Depending upon the level of the patient’s risk
and the complexity of the issues involved, co-evaluation with a cardiologist familiar
with these cardio-oncologic issues may be appropriate. Davis and Witteles review
strategies for cardiac testing in cancer patients at high risk of cardiac complications.
In order to assess and treat the long-term risk of developing cardiac disease in
cancer survivors, Carver et al propose a comprehensive diagnostic and therapeutic
strategy.

Although cardiovascular toxicity including left ventricular systolic dysfunction,
heart failure, hypertension, coronary ischemia, pericardial disease, and arrhythmias
may develop from all of the classes of cancer therapy, a variety of cancers
themselves may adversely affect the cardiovascular system as well. Bonita and
Pradhan review the possible toxicities of the chemotherapeutic agents, while Ryberg
discusses the cardiac concerns related to treatment with the biologic agents. The

cardiotoxic effects of radiation therapy are discussed by Martinou and Gaya.
Regarding cancer-induced cardiac toxicity, Lenihan et al review the evaluation and
management of infiltrative cardiomyopathies and pericardial disease.

Rather than only identifying patients who may have developed overt cardiac toxicity
from their cancer-related disease, the ultimate goal for both the oncologist and the
cardiologist is to prevent the development of these complications. Cardinale et al
review the literature with regard to promising strategies in this area and share the
available data regarding treatment options.

In addition to the insults that occur to the cardiovascular system as a result of a
patient’s cancer or their cancer treatment, a patient’s oncologic status may also be
affected by their preexisting cardiovascular disease. Many cancer patients will
already be maintained on the kind of complex cardiovascular drug regimen that has
led to improved survival among cardiac patients. Chen and Parameswaran review
how these cardiac agents will affect a cancer patient’s clinical status and therapeutic
treatment options.

Given the interplay between oncologic and cardiac disease states, Jones et al explore
the risk factors common to both of these conditions and demonstrate the data that
support a preventive treatment strategy, including exercise, that might be effective
in decreasing the incidence of both cancer and cardiac disease.

In an era when more effective detection and treatment of both oncologic and
cardiovascular disease states are available, it is incumbent upon treating physicians
to be aware of the complicating issues that may negatively impact the prognosis of
these patients. More outcomes data is needed to guide specific care
recommendations, but in the meantime, close consultation between oncologists and
cardiologists is required for the optimal management of patients who have, or who
are at risk for developing, cardio-oncologic disease.
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